You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CDK4 amplification

Showing 1 - 25 of 2,094
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Cancer Trial in Boston (Abemaciclib)

Recruiting
  • Cancer
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Jan 9, 2023

GBM, Glioblastoma, Brain Tumor Trial in Dallas (Abemaciclib, Bevacizumab)

Active, not recruiting
  • GBM
  • +3 more
  • Dallas, Texas
    UT Southwestern Medical Center
Jan 23, 2022

CDK4/6 Inhibitors Combined With Endocrine Therapy and Subsequent

Not yet recruiting
  • Breast Cancer
  • +3 more
  • Different treatment regimens following progression on CDK4/6 inhibitors.
  • (no location specified)
Sep 5, 2023

Head Neck Cancer, Advanced Cancer, Metastatic Cancer Trial in Bordeaux, Lyon, Nice (Abemaciclib)

Recruiting
  • Head and Neck Cancer
  • +2 more
  • Bordeaux, France
  • +2 more
Jul 22, 2022

CDK4/6 Inhibitors in Hormone Receptor-positive Advanced Breast

Not yet recruiting
  • Breast Cancer
  • CDK4/6 inhibitor
  • Shanghai, Shanghai, China
    Renji Hospital, School of Medicine, Shanghai Jiao Tong Universit
Apr 5, 2023

Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed Trial in Hangzhou (dalpiciclib;

Recruiting
  • Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed
  • dalpiciclib; fluvestrant; compound gossypol acetate tablets
  • Hangzhou, Zhejiang, China
    zhejiangCH
Nov 9, 2023

Advanced Malignant Solid Tumor, EGFR Gene Amplification, EGFR Gene Mutation Trial in Houston (Everolimus, Neratinib,

Recruiting
  • Advanced Malignant Solid Neoplasm
  • +9 more
  • Houston, Texas
    M D Anderson Cancer Center
Oct 25, 2022

Locally Advanced Breast Cancer, Hormone Receptor Positive,HER2-negative Breast Cancer Trial in Jinan (letrozole)

Recruiting
  • Locally Advanced Breast Cancer
  • Hormone Receptor Positiveļ¼ŒHER2-negative Breast Cancer
  • Jinan, Shandong, China
    Breast Cancer Center, Shandong Cancer Hospital and Institute
Apr 11, 2023

Tumors Trial in Seoul (abemaciclib+paclitaxel)

Active, not recruiting
  • Tumors
  • Seoul, Korea, Republic of
    Severance Hospital
May 30, 2022

Learn About Use and Effects of CDK4/6 Inhibitors in Canadian

Active, not recruiting
  • Breast Cancer
    • Kirkland, Quebec, Canada
      Pfizer Canada
    Mar 5, 2023

    Advanced HR+ HER2 Negative Breast Carcinoma Trial ((CDK)4/6 inhibitor)

    Not yet recruiting
    • Advanced HR+ HER2 Negative Breast Carcinoma
    • (CDK)4/6 inhibitor
    • (no location specified)
    Sep 27, 2022

    Estrogen-receptor-positive Breast Cancer, HER2/Neu-Negative Breast Cancer, Advanced Breast Cancerv Trial in Chicago

    Not yet recruiting
    • Estrogen-receptor-positive Breast Cancer
    • +3 more
    • elacestrant, palbociclib, abemaciclib, ribociclib
    • Chicago, Illinois
      Northwestern University
    Sep 25, 2023

    Advanced Breast Cancer Trial in Beijing (The combination of Dalpiciclib with physician-selected endocrine therapy, Chemotherapy

    Recruiting
    • Advanced Breast Cancer
    • The combination of Dalpiciclib with physician-selected endocrine therapy
    • Chemotherapy selected by the physician
    • Beijing, Beijing, China
      Peking Union Medical College Hospital
    May 22, 2023

    Hormone Receptor-positive Advanced Breast Cancer Trial (chidamide combined with fulvestrant)

    Not yet recruiting
    • Hormone Receptor-positive Advanced Breast Cancer
    • chidamide combined with fulvestrant
    • (no location specified)
    Mar 28, 2023

    Advanced Breast Cancer Trial in Lebanon (Fulvestrant, Neratinib, Alpelisib)

    Not yet recruiting
    • Advanced Breast Cancer
    • Lebanon, New Hampshire
      Dartmouth Hitchcock Medical Center
    Jun 28, 2023

    Breast Cancer Trial in Baltimore (Endocrine Therapy and a CDK 4/6 inhibitor)

    Recruiting
    • Breast Cancer
    • Endocrine Therapy and a CDK 4/6 inhibitor
    • Baltimore, Maryland
      Johns Hopkins University
    Jul 18, 2022

    Metastatic Breast Cancer Trial (Elacestrant)

    Not yet recruiting
    • Metastatic Breast Cancer
    • (no location specified)
    Oct 24, 2022

    CYP3A4*22 Trial (Palbociclib 125Mg Tab, Ribociclib 200Mg Oral Tablet, Abemaciclib 150 MG Oral Tablet)

    Not yet recruiting
    • CYP3A4*22
    • Palbociclib 125Mg Tab
    • +2 more
    • (no location specified)
    Jan 10, 2023

    Breast Cancer Metastatic Cancer Trial in Shanghai (Apatinib, Dalpiciclib, Fulvestrant/AI)

    Recruiting
    • Breast Cancer Metastatic Cancer
    • Shanghai, Shanghai, China
      Breast cancer institute of Fudan University Cancer Hospital
    Feb 26, 2023

    Breast Cancer Trial (RP-6306, Gemcitabine, Observation)

    Not yet recruiting
    • Breast Cancer
    • (no location specified)
    Jan 26, 2023

    Inhibition of Autophagy Synergizes Anti-tumor Effect Trial in Guangzhou (100mg bid dose of hydroxychloroquine combined with

    Recruiting
    • Inhibition of Autophagy Synergizes Anti-tumor Effect
    • 100mg bid dose of hydroxychloroquine combined with three predefined dose groups of palbociclib
    • RP2D dose of 100mg bid of hydroxychloroquine combined with palbociclib was selected for phase II clinical trial.
    • Guangzhou, Guangdong, China
      Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
    Jul 19, 2023

    Breast Cancer Metastatic Cancer Trial in Shanghai (Fluzoparib, Dalpiciclib, Fulvestrant/AI)

    Recruiting
    • Breast Cancer Metastatic Cancer
    • Shanghai, Shanghai, China
      Breast cancer institute of Fudan University Cancer Hospital
    Feb 26, 2023

    Breast Cancer Trial (Abemaciclib, Letrozole)

    Not yet recruiting
    • Breast Cancer
    • (no location specified)
    Nov 14, 2023

    HR+/HER2- Advanced Breast Cancer Trial in Beijing (Dalpiciclib, Chidamide)

    Not yet recruiting
    • HR+/HER2- Advanced Breast Cancer
    • Beijing, Beijing, China
      The Fifth Medical Center of PLA General Hospital
    Oct 17, 2022

    Breast Cancer Trial in Tianjin (Dalpiciclib, Pyrotinib, Fulvestrant)

    Not yet recruiting
    • Breast Cancer
    • Tianjin, China
      Tianjin Cancer Hospital
    Mar 28, 2023